Fornecker, L., Lazarovici, J., Aurer, I., Casasnovas, R., Gac, A., Bonnet, C., Bouabdallah, K., Feugier, P., Specht, L., Molina, L., Touati, M., Borel, C., Stamatoullas, A., Nicolas-Virelizier, E., Pascal, L., Lugtenburg, P., Di Renzo, N., Vander Borght, T., Traverse-Glehen, A., Dartigues, P., Hutchings, M., Versari, A., Meignan, M., Federico, M., André, M., & , (2023). brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of clinical oncology, 41(2), 327–335. http://access.bl.uk/ark:/81055/vdc_100174260717.0x000004